8-K: Castle Biosciences Exceeds 2025 Revenue Guidance

Castle Biosciences announced preliminary unaudited Q4 and full-year 2025 results, with total revenue exceeding $340 million, above previous guidance, driven by strong growth in core diagnostic tests.

Summary

• 2025 total revenue is expected to exceed $340 million, surpassing the previously guided range of $327-335 million.
• Total test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased 37% over 2024.
• Year-end 2025 cash, cash equivalents, and marketable investment securities are expected to be approximately $300 million.
• AdvanceAD-Tx, a new test for atopic dermatitis, launched on a limited access basis in November 2025, with over 50% of granted clinician offices ordering within five weeks.
• DecisionDx-SCC test reports decreased in Q4 2025 compared to Q4 2024, affected by a change in Medicare coverage.
• The IDgenetix test offering was discontinued effective May 2025.

Sentiment

Score: 8

Explanation: The company reported strong preliminary financial results, exceeding revenue guidance and showing significant growth in core diagnostic test volumes. The successful launch of a new test expanding the addressable market and a healthy cash balance contribute to a very positive outlook, despite some minor declines in specific test volumes and the discontinuation of one product.

Positives

• 2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million.
• Core revenue drivers (DecisionDx-Melanoma, TissueCypher) saw a 37% increase in total test reports for full-year 2025 over 2024.
• TissueCypher Barrett's Esophagus test reports delivered 86% volume growth for the full year 2025 compared to 2024.
• DecisionDx-Melanoma achieved 9% volume growth for full year 2025 over 2024.
• Successful limited access launch of AdvanceAD-Tx in November 2025, with over 50% of initial clinician offices ordering the test.
• Strong balance sheet with year-end 2025 cash, cash equivalents, and marketable investment securities expected to be approximately $300 million.
• Expansion of total addressable market with the launch of AdvanceAD-Tx.

Negatives

• DecisionDx-SCC test reports decreased to 3,971 in Q4 2025 from 4,299 in Q4 2024, impacted by a change in Medicare coverage.
• DecisionDx-UM test reports decreased to 395 in Q4 2025 from 424 in Q4 2024.
• Discontinuation of the IDgenetix test offering in May 2025, leading to a significant drop in test reports from 17,151 in 2024 to 3,605 in 2025.

Risks

• Preliminary, unaudited financial information is subject to adjustment and may differ materially from audited financial statements.
• Assumptions or expectations regarding reimbursement for products and subsequent coverage decisions may not materialize.
• Estimated total addressable markets for products and product candidates may not be accurate.
• The anticipated cost, timing, and success of product candidates are uncertain.
• Ability to successfully integrate new businesses, assets, products, or technologies acquired through acquisitions.
• Effects of macroeconomic events and conditions, including inflation, monetary supply shifts, labor shortages, liquidity concerns at financial institutions, recession risks, supply chain disruptions, tariffs, outbreaks of contagious diseases, and geopolitical events.
• The possibility that subsequent study or trial results and findings may contradict earlier results or not support the benefits discussed.
• Planned installation of additional equipment and technology infrastructures may not increase the future scalability of the TissueCypher Test as anticipated.
• Actual application of tests may not provide the anticipated benefits to patients.
• Newer gastroenterology and mental health franchises may not contribute to long-term financial targets as anticipated.

Future Outlook

The company is positioned for continued growth and value creation, particularly with the expansion into atopic dermatitis through AdvanceAD-Tx, which materially expands its total addressable market. Management believes the strong balance sheet and execution across dermatologic and gastrointestinal franchises position the company well for growth opportunities in 2026 and beyond.

Management Comments

• "We are extremely pleased with our excellent fourth quarter and full year preliminary results, which reflect both the strength of our innovative test portfolio and the dedication of the entire Castle team."
• "We exited 2025 exhibiting strong execution and leadership across our dermatologic and gastrointestinal franchises and a strong balance sheet, positioning us well, we believe, to capitalize on our growth opportunities in 2026 and beyond."

Industry Context

Castle Biosciences operates in the specialized diagnostics sector, focusing on dermatologic and gastroenterological diseases. The launch of AdvanceAD-Tx for atopic dermatitis signifies a strategic expansion into a new, large market, potentially diversifying revenue streams beyond its established melanoma and Barrett's esophagus tests. The company's growth in core drivers suggests strong demand for its personalized, clinically actionable solutions in a competitive diagnostics landscape.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Positive impact due to exceeding revenue guidance, strong growth in core products, successful new product launch, and a healthy balance sheet, potentially leading to increased share value.
• Patients: Improved care guidance through innovative diagnostic tests, especially with the new AdvanceAD-Tx test for atopic dermatitis.
• Clinicians: Access to new and existing diagnostic tools to guide patient care decisions.
• Employees: Recognition as a "Houston Top Workplace" suggests a positive internal environment, and strong company performance could lead to job security and growth opportunities.

Next Steps

• Completion of end-of-period reporting processes and related activities.
• Audit by the independent registered public accounting firm of the company's financial statements.
• Reporting of audited consolidated financial statements and complete financial and operational results for fiscal year ended December 31, 2025, expected in February 2026.
• Continued capitalization on growth opportunities in 2026 and beyond.
• Advancing penetration of tests with clinicians and payers.
• Ongoing studies generating data to drive adoption of tests.

Key Dates

Recommendation

The company has demonstrated robust financial performance, exceeding its revenue guidance for 2025 and showing significant year-over-year growth in its core diagnostic test volumes, particularly TissueCypher. The successful limited launch of AdvanceAD-Tx for atopic dermatitis represents a material expansion into a large new market, indicating strong strategic execution and future growth potential. A healthy cash position of approximately $300 million provides financial stability. While there were minor declines in some test volumes and the discontinuation of IDgenetix, these are overshadowed by the overall positive trajectory and strategic advancements. These factors suggest strong operational momentum and a favorable outlook for investors.

Keywords

Castle Biosciences, CSTL, Preliminary Results, Q4 2025, Full Year 2025, Revenue Guidance, Diagnostic Tests, Melanoma, Barrett's Esophagus, Atopic Dermatitis, AdvanceAD-Tx, TissueCypher, DecisionDx-Melanoma, Financial Performance, Biotechnology, Medical Diagnostics, SEC Filing